Mantle Cell Lymphoma: Effectiveness of Maintenance Ibrutinib – Case Report

Abstract

Mantle cell lymphoma is a rare subtype of non- Hodgkin lymphoma with life-threatening course of disease. It mostly affects older adults in their sixth or seventh decade of life with male to female predominance of 3 to 1. It prognosis is very poor and the treatment is demanding. The golden standard therapy for younger, fit patients <65 years is chemoimmunotherapy such as R-CHOP/R-DHAP rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, prednisolone, dexamethasone, cytarabine and cisplatin) followed by BEAM chemotherapy (carmustine, etoposide, cytarabine, melphalan) and autologous- stem-cell transplant (ASCT). Nevertheless MCL is mainly recognized in patients of average age 67 in whom comorbidities often play a crucial role during treatment.A 56- years old patient was admitted to the Department of Hematooncology and Bone Marrow Transplantation with clinical symptoms such as heavy night sweats, generalized enlargement of lymph nodes, massive weight loss, dyspnea and fatigue. Initial physical examination and imaging showed enormous hepatosplenomegaly, mass in the lungs and fluid in the pleural cavity.The patients underwent chemioimmunotherapy consolidated with an autologous stem cell transplant. To date, the patient is on maintenance treatment with ibrutinib.

Keywords

• mantle cell lymphoma
• ibrutinib
• maintenance therapy